The global biotech market which was $1023.92 billion in 2022, is expected to reach $10129.16 billion by 2030. Unlike many sectors, biotech attracted record levels of investment during COVID. Japan and Korea, two of the largest Asian markets, present a host of opportunities. Hear from key industry speakers from both markets to learn of best practices and opportunities as well as, from the U.S. Dept. of Commerce to hear about USG biotech trade policy developments. A question & answer session to follow. California Life Science and the U.S. Commercial Service in San Francisco, Japan, and Korea, have worked together to bring this event to you. We look forward to sharing how USG assistance can help your company expand globally.
Personalized Medicine, Gene Therapy, Immunology, Genetic Diagnostics, Tissue Engineering & Regeneration, Nano biotech, Biopharma
Maria Elena Rivero, Senior Int’l Trade Specialist, U.S. Commercial Service San Francisco
Stacey Bowlin, Senior Vice President, Industry Engagement, California Life Sciences
Yuanyuan Milligan, Biopharma Policy Analyst, U.S. Dept of Commerce
Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA)
Jurie Hwang | Director, Public & International Relations, KoreaBIO
